Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasenra for eosinophilic gastritis and/or gastroenteritis (HUDSON)
CTR20222544Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of benralizumab in eosinophilic gastritis (EG), eosinophilic enteritis (EoN), eosinophilic duodenitis (EoD), sponsored by AstraZeneca. Started Oct 2022; status: terminated.
02
Drugs
benralizumab
03
Conditions
eosinophilic gastritis (EG)eosinophilic enteritis (EoN)eosinophilic duodenitis (EoD)
Beyond the preview
Go deeper on CTR20222544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222544.